News & Media




COVID-19 information

Iris Pharma remains fully operational during the COVID-19 pandemic. Read our response to COVID-19.

#TogetherAgainstCovid19 – Stay Safe




Attractive tax measures with Iris Pharma: renewal of French research tax credit accreditation

April, 11 2022 - Iris Pharma obtains renewal of its accreditation for the research tax credit (CIR) by the French Ministry Responsible for Research, insuring its potential to do research and development, product innovation or work to develop a new range of products. Continue reading




Animal model for wet or exudative form of age-related macular degeneration induced by DL-α-aminoadipic acid (AAA)

March 23, 2022 - […] This suitable model is useful to evaluate the relative therapeutic efficacy of a compound in inhibiting retinal vascular leakage and neovascularization. […] Continue reading




Animal model for dry age-related macular degeneration and retinitis pigmentosa induced by N-methy-N-nitrosourea (MNU)

January 03, 2022 - Iris Pharma has developed a new animal model to mimic retinal degenerative diseases like dry age-related macular degeneration (AMD) and retinitis pigmentosa (RP). […] Continue reading




Statement of GLP compliance renewal

October 25, 2021 - Iris Pharma’s preclinical facility received once more a GLP certificate from the French National Agency for Medicines and Health Products' Safety (ANSM). 
Status “A” for human medicines, and “in conformity with GLP” for medical devices! Continue reading





Dry eye syndrome animal model

May 2, 2020 - Two new preclinical rodent models induced by extraorbital lacrimal gland excision (LGE) to mimic symptoms of dry eye syndrome in the human eye […] Dry eye disease is induced by extraorbital lacrimal gland excision, a highly technical procedure performed by our expert technicians in ocular surgery. The induction causes moderate to severe aqueous tear deficiency as well as ocular surface damage. […] Continue reading




Chronic uveitis animal model

May 1, 2019 - Chronic uveitis: a new preclinical model of chronic uveitis to evaluate efficacy of long-term treatment or delivery medical devices […] Continue reading




Iris Pharma celebrates its 30th anniversary!

January 27, 2019 - Iris Pharma has partnered with clients to bring nearly 70 ocular drugs and medical devices to market in the past 30 years, in addition to offering consulting services to help clients determine the best indication for molecules and products in development.

Thanks to our customers, collaborators, international ophthalmologists and expert partners who have worked with us since the beginning!




Keen Eye and Iris Pharma Team up to Bring Artificial Intelligence in Ophthalmology Studies

October, 2018 - Keen Eye and Iris Pharma team up to bring AI in the preclinical ophthalmic drug development to make assays faster, more reliable and more efficient. […] Continue reading




Streetlab and Iris Pharma: a Partnership Aimed at Integrating Quality of Life in the Clinical Assessment of New Products for Use by the Visually Impaired

February, 2017 - Streetlab, a company which works to improve independence, mobility and quality of life for the visually impaired, has announced a strategic partnership agreement with Iris Pharma, an ophthalmology-focused contract research organization (CRO) that offers preclinical and clinical drug / device development services. This partnership forms the basis of a new service offer for the pharmaceutical industry, with the integration of a methodological approach which is focused on human factors in the assessment of new drugs, medical devices or technologies for the use of partially sighted people. […] Continue reading



Streetlab et Iris Pharma : un partenariat pour l’intégration de la qualité de vie dans l’évaluation clinique de nouveaux produits à l’usage des malvoyants

Février 2017 - Streetlab, société œuvrant à l'amélioration de l’autonomie, de la mobilité et de la qualité de vie des personnes déficientes visuelles annonce la signature d’un accord de partenariat stratégique avec la société Iris Pharma, société de recherche sous contrat spécialisée dans le développement de médicaments et dispositifs médicaux dans le domaine de l’ophtalmologie. […] Poursuivre la lecture




Yann Quentric named Iris Pharma’s company President

July, 2015 - Yann Quentric will be stepping into the role of company President at Iris Pharma. Yann succeeds Pierre-Paul Elena, who transferred to the role of Chairman of the Supervisory Board and Chief Scientic Officer.


Media & Booklets



IRIS PHARMA BOOKLET: Download the booklet




IRIS PHARMA Fact Sheet: Download the flyer



Eye preclinical research


IRIS PHARMA PAPERS & POSTERS - section preclinical services: Download the flyer



Eye clinical research


IRIS PHARMA PAPERS & POSTERS - section clinical research: Download the flyer